Metraipolis › archive › dc_4df9511d76ec

The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter… — Europe PMC PMID:40944727

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40944727
DOI
10.1007/s00262-[numero omesso]-5
License (as archived)
solo-consultazione
Archived
2026-11-09T23:45:34.448Z
SHA-256 of the archived text
5a95808498f4c4b45a7b402efc61405904fed5a3058c5a2d6b1baaf594ac10a9
Stable URL of this page
https://metraipolis.com/documento/dc_4df9511d76ec

How to cite

The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter… — Europe PMC PMID:40944727 — Europe PMC (en), https://europepmc.org/article/MED/40944727 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4df9511d76ec (Metraipolis archive dc_4df9511d76ec, sha256 5a95808498f4c4b45a7b402efc61405904fed5a3058c5a2d6b1baaf594ac10a9)
BibTeX
@misc{dc4df9511d76ec,
  title = {The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter… — Europe PMC PMID:40944727},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40944727},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4df9511d76ec; sha256 5a95808498f4c4b45a7b402efc61405904fed5a3058c5a2d6b1baaf594ac10a9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40944727. Agents can read the archived copy with the MCP tool read_document.